S15 Ep47: ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

In today’s episode, the discussion features Komal Jhaveri, MD, FACP, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, who reviewed the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in the management of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. She drew on findings from the phase 3 ASCENT-07 trial (NCT05840211), which evaluated sacituzumab govitecan-hziy (Trodelvy) in the first-line setting following endocrine therapy for patients with HR-positive, HER2-negative metastatic breast cancer.

In this exclusive interview, Dr Jhaveri discussed the rationale for evaluating sacituzumab govitecan earlier in the treatment paradigm, summarized key efficacy outcomes from ASCENT-07, and contextualized why the trial did not meet its primary progression-free survival end point. She also highlighted how disease biology and patient selection may influence outcomes when ADCs are moved into earlier lines of therapy, and outlined practical considerations for toxicity management and future trial design as the TROP2 ADC landscape continues to evolve.
asts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!